Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Elevated Levels of IgG2 Antibodies Protect Some Types of Gram-Negative Bacteria

By BiotechDaily International staff writers
Posted on 27 Aug 2014
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
The finding that an overabundance of a certain class of antibodies protects some bacteria from the effects of antibiotics has marked implications for our understanding of the protection generated by natural infections and for the design of vaccines, which should avoid inducing such inhibitory antibodies.

Investigators at the University of Birmingham (United Kingdom) worked with patients that had bronchiectasis—a chronic infection characterized by persistent cough, shortness of breath, and chest pain—or lung infection caused by the bacterium Pseudomonas aeruginosa.

They reported in the August 2014 online edition of the Journal of Experimental Medicine that in a significant portion of these patients, antibodies protected the bacterium from complement-mediated killing. Strains that resisted antibody-induced, complement-mediated killing produced a lipopolysaccharide containing O-antigen. In particular, they found that inhibition of antibody-mediated killing was caused by excess production of O-antigen–specific antibodies of the IgG2 class. Depletion of IgG2 to O-antigen restored the ability of sera to kill strains with long-chain O-antigen.

Patients with impaired serum-mediated killing of P. aeruginosa by IgG2 were shown to have poorer respiratory function than infected patients who did not produce the inhibitory antibody.

The authors suggested that excessive binding of IgG2 to O-antigen shielded the bacterium from other antibodies that could induce complement-mediated killing. Since there is significant sharing of O-antigen structure between different Gram-negative bacteria, this IgG2-mediated impairment of killing could be operating in other Gram-negative infections as well. These findings have marked implications for understanding the nature of protection generated by natural infections and for the design of vaccines, which should avoid inducing IgG2 class inhibitory antibodies.

Related Links:

University of Birmingham 



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.